INS and Insulin resistance: Clinical trials, including a large-scale RCT (n = 535), have demonstrated that chiglitazar sodium effectively reduces HbA1c, improves fasting plasma insulin, and enhances measures of β-cell function (HOMA-β) and insulin resistance (HOMA-IR) (22).